-
Product Insights
MRI Systems Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
MRI Systems Pipeline Market Report Overview Magnetic Resonance Imaging (MRI) generates clear and detailed images of internal organs and tissues using radiofrequency and a strong magnetic field. MRI is generally preferred for the diagnosis of brain and other neurological disorders. The 3T, 1.5T and 0.2-1.2T MRI systems have been tracked under this category. The MRI Systems pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report...
-
Product Insights
1.5T MRI Systems Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
1.5T MRI Systems Pipeline Market Report Overview The 1.5T MRI Systems pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Territories · Europe · India · United States · China Key Regulatory Paths · CE · ICAC...
-
Sector Analysis
Magnetic Resonance Imaging (MRI) Systems Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033
Magnetic Resonance Imaging (MRI) Systems Market Report Overview The magnetic resonance imaging (MRI) systems market size was valued at $5.21 billion in 2023 and is forecast to grow at a CAGR of over 6% during the forecast period. MRI systems are non-invasive diagnostic imaging system that utilizes strong magnetic fields. It aids in the detection & diagnosis of various conditions and the assessment of the patient's progress. MRI is useful for examinations of soft tissues & nervous system. Magnetic Resonance...
-
Product Insights
NewLikelihood of Approval Analysis for Secondary Progressive Multiple Sclerosis (SPMS)
Overview How likely is it that the drugs in Secondary Progressive Multiple Sclerosis (SPMS) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Secondary Progressive Multiple Sclerosis (SPMS) Overview Secondary progressive multiple...
-
Product Insights
NewLikelihood of Approval Analysis for Adrenal Gland Disorders
Overview How likely is it that the drugs in Adrenal Gland Disorders will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Adrenal Gland Disorders Overview Adrenal gland disorders comprise various conditions impacting...
-
Product Insights
NewLikelihood of Approval Analysis for Juvenile Arthritis
Overview How likely is it that the drugs in Juvenile Arthritis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Juvenile Arthritis Overview Juvenile arthritis (JA), also known as pediatric rheumatic disease,...
-
Product Insights
NewLikelihood of Approval Analysis for Cerebrovascular Disease
Overview How likely is it that the drugs in Cerebrovascular Disease will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cerebrovascular Disease Overview Cerebrovascular disease refers to a group of conditions that...
-
Product Insights
NewLikelihood of Approval Analysis for Neuroblastoma
Overview How likely is it that the drugs in Neuroblastoma will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Neuroblastoma Overview Neuroblastoma is the cancer of the nerve tissues and neural crest...
-
Product Insights
NewLikelihood of Approval Analysis for Tenosynovial Giant Cell Tumor
Overview How likely is it that the drugs in Tenosynovial Giant Cell Tumor will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tenosynovial Giant Cell Tumor Overview Tenosynovial Giant Cell Tumors are...
-
Product Insights
NewLikelihood of Approval Analysis for Malignant Fibrous Histiocytoma
Overview How likely is it that the drugs in Malignant Fibrous Histiocytoma will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Malignant Fibrous Histiocytoma Overview Malignant fibrous histiocytoma, now termed undifferentiated pleomorphic...